Prevention of bone loss by hormone replacement therapy is probably not due to stimulation of calcitonin secretion.
Weekly fasting serum calcitonin levels and biochemical indices of bone metabolism were measured in 13 postmenopausal women being given hormone replacement therapy over a period of 8 weeks. All of the biochemical indices except urinary hydroxyproline creatinine ratios fell significantly, indicating that the treatments were effective in reducing bone turnover. Calcitonin levels fell significantly and, within the individual, levels were positively correlated with adjusted calcium levels. These findings do not support the theory that estrogen conserves bone by stimulating calcitonin secretion.
Fletcher
C D
CD
Department of Biochemistry, Stobhill General Hospital, Glasgow, Scotland.
Farish
E
E
Leggate
J
J
Hart
D M
DM
D000469:Alkaline Phosphatase / Q000097:blood; D001842:Bone and Bones / Q000378:metabolism / Q000502:physiology; D002116:Calcitonin / Q000097:blood* / Q000502:physiology; D002118:Calcium / Q000097:blood / Q000652:urine; D003404:Creatinine / Q000652:urine; D015914:Estrogen Replacement Therapy; D004967:Estrogens / Q000494:pharmacology / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D006909:Hydroxyproline / Q000652:urine; D008593:Menopause / Q000097:blood / Q000502:physiology / Q000652:urine; D008875:Middle Aged; D015663:Osteoporosis, Postmenopausal / Q000378:metabolism / Q000503:physiopathology / Q000517:prevention & control*; D010710:Phosphates / Q000097:blood; D011374:Progesterone / Q000494:pharmacology / Q000627:therapeutic use*
D004967:Estrogens; D010710:Phosphates; D011374:Progesterone; D002116:Calcitonin; D003404:Creatinine; D000469:Alkaline Phosphatase; D006909:Hydroxyproline; D002118:Calcium